Evidence map›Paper›PMID 32063772›Full record

ArticleProceedings (Baylor University. Medical Center)2020

Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma.

James Lopez, Naveen Yarlagadda, Zaid Gheith, Meera Mohan, Appalanaidu Sasapu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

James LopezDepartment of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.ORCID 0000-0002-3654-3205
Naveen YarlagaddaDepartment of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
Zaid GheithDepartment of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
Meera MohanDepartment of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
Appalanaidu SasapuDepartment of Hematology/Oncology, University of Arkansas for Medical SciencesLittle RockArkansas.
University of Arkansas for Medical Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nivolumab, a monoclonal antibody against programmed cell death-1 used to treat multiple cancers, has fewer side effects than traditional chemotherapy but has displayed a propensity to cause a host of immune-related adverse events. We describe a case of nivolumab immune-mediated neurotoxicity in a 42-year-old Hispanic man with relapsed Hodgkin lymphoma who presented with unilateral facial droop, dysarthria, and dysphagia 1 week after receiving nivolumab. His symptoms rapidly improved with steroids, intravenous immunoglobulin, and infliximab.

Indexed as

Hodgkin lymphomaimmune-mediated adverse reactionneurotoxicitynivolumab

Identifiers

PMID32063772
PMCPMC6988700
OpenAlexW2981384452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.